Mountain Valley MD Holdings Inc. announced that the Company has filed a novel cancer adjuvant patent and is proceeding with pre-clinical trials with third-party cancer Contract Research Organizations (CROs) in triple-negative breast cancer, metastatic melanoma, and lung carcinoma. Leading up to the implementation of pre-clinical trial cancer research, MVMD has been extensively researching the drug ivermectin, including its impact on cancer, and has included numerous abstracts at the end of this media release. All of the research articles cited involve either existing oral ivermectin in a murine model or the in-vitro testing of ivermectin utilizing organic solvents for solubilization that would be prohibited in a human intravenous or intratumoral administration. MVMD filed its cancer adjuvant patent, Novel Injectable, Infusable, Instillable Ivermectin Adjuvant for Cancer Therapies for its solubilized ivermectin (Ivectosol™). The patent-pending adjuvant utilizes the Company's advances in macrocyclic lactone solubility to consider Ivectosol™ as a viable adjuvant for numerous cancer therapies. MVMD's solubility technology applied to the ivermectin drug is the only form in the world that uses strictly excipients that are currently approved by the US Food and Drug Administration (FDA), making it a leading candidate for human injection or intravenous infusion. The pre-clinical trials that are being conducted are designed to prove the utility of Ivectosol™ to synergize and improve various cancer regimens currently in use and as a potent enhancer of current immunotherapies and chemotherapies for difficult to treat cancers. Study One: Triple-negative breast cancer: Study will test the effectiveness of Ivectosol™ combined with checkpoint inhibitor that would be equivalent to either OPDIVO or Keytruda for disease progression and complete response rate. Arms in the study will look at single checkpoint inhibitor, oral IVM + checkpoint inhibitor and intratumoral IVM + checkpoint inhibitor. Estimated initial readouts/analysis – 2nd week of June, 2021. Complete readout with flow cytometry and statistical evaluation estimated mid-July, 2021 with possible abstract submission in August, 2021. Study Two: Metastatic melanoma: Study will test the effectiveness of Ivectosol™ intratumoral combined with checkpoint inhibitor for disease progression and complete response rate. Arms in the study will look at single checkpoint inhibitor, oral IVM + checkpoint inhibitor and intratumoral IVM + checkpoint inhibitor. Estimated initial readouts by end of June, 2021. Complete readout with flow cytometry and statistical evaluations estimated end of July, 2021 with possible abstract submission in August, 2021. Study Three: Lewis lung carcinoma as a proxy for non-small cell lung carcinoma: Study will test the effectiveness of Ivectosol™ intratumorally combined with checkpoint inhibitor for disease progression and complete response rate. Arms in the study will look at single checkpoint inhibitor, oral IVM + checkpoint inhibitor, intratumoral IVM + checkpoint inhibitor, navalbine + intratumoral IVM. Estimated initial readouts by end of June, 2021. Complete readouts with flow cytometry and statistical evaluation estimated by end of July, 2021 with possible abstract submission in August, 2021. All three studies will assess tumor growth and metastases through bioluminescence imaging, a non-invasive optical imaging modality designed to visualize and quantify bioluminescent signal in tissues. The Company is also actively pursuing a pre-clinical trial for bladder cancer and is currently assessing the best option to proceed through the evaluation of CRO proposals.